Latest Breaking News On - Bnt211 01 trial - Page 1 : comparemela.com

The Claudin-6–directed CAR T-cell therapy, BNT211, showed signs of clinical activity in patients with CLDN6-positive relapsed or refractory solid tumors.

Roche genentechMerck seronoIovance bioAsher bioTranslational immunotherapy of cancer at leiden universityBristol myers squibbLeiden universityInstil bioMolecular partnersNeogene therapeuticsThird rock venturesSastra cellSolid tumorsCart cell therapyBnt211 01 trial